FDA Approves First Gene-Based Test to Detect the Spread of Breast Cancer Into Lymph Nodes

Veridex, LLC, a Johnson & Johnson company, has announced U.S. Food and Drug Administration (FDA) approval of the first intra-operative and gene-based test to detect the spread of breast cancer into the lymph nodes. The GeneSearch(TM) Breast Lymph Node (BLN) Assay can detect the spread of cancer into the lymph nodes more accurately than existing rapid methodologies and, as a result, has the potential to reduce the need for stressful and costly second surgeries for breast cancer patients.